Suspected local disease regrowth was seen in 23% of patients with rectal cancer observed following a near or complete clinical response to neoadjuvant therapy.
Get the latest treatment options for rectal cancer, including concurrent chemotherapy and radiotherapy and levoleucovorin plus 5-FU.
Early results from the Polish II study showed a significant improvement in OS for preoperative short-course RT/chemotherapy compared with long-term chemo-RT.
Researchers sought to measure adherence to topical management regimens among patients with HFSR due to treatment with regorafenib.
A retrospective review of data from the National Cancer Data Base demonstrated that trends in rectal cancer may follow a pattern similar to that of colon cancer.
Incidence of colon and rectal cancers are increasing sharply in people younger than 50 years, the recommended age for initiating screening.
Outcomes improved with short-course radiation and delay to surgery of 4 to 8 weeks.
In this study, the impact of advancements in surgical technique and systemic therapy for stage II and III rectal cancers was assessed via a comparison of outcomes after neoadjuvant chemoradiotherapy followed by definitive resection with those for neoadjuvant multiagent chemotherapy without radiation therapy.
Poor compliance to NCCN guidelines for adjuvant chemotherapy appears to be associated with poorer overall survival.
Use of neoadjuvant chemoradiotherapy (NACRT) before surgery among patients with rectal cancer has substantially increased over the past decade.
